MIM
JNCE

MetLife Investment Management’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

MetLife Investment Management’s Portfolio JNCE Stock Details JNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-1,671
Closed -$14K – 2786
2021
Q4 		$14K Sell
1,671
-10,976
-87% -$90.4K ﹤0.01% 2490
2021
Q3 		$94K Buy
+12,647
New +$78.3K ﹤0.01% 2466
2018
Q2 		– Sell
-7,132
Closed -$159K – 2237
2018
Q1 		$159K Buy
+7,132
New +$158K ﹤0.01% 2009

Other funds holding JNCE

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

MetLife Investment Management's JNCE Position: Q1 2022 in Review

MetLife Investment Management sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q1 2022, closing a stake of 1,671 shares — an estimated $14K sold.

MetLife Investment Management first reported a position in JNCE in Q1 2018 and held it in 3 quarters. The position peaked at $159K in Q1 2018. 113 funds tracked by Wall St. Rank hold JNCE as of Q1 2022.

  • MetLife Investment Management reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
  • MetLife Investment Management sold 1,671 Jounce Therapeutics, Inc. Common Stock shares in Q1 2022, an estimated $14K.
  • MetLife Investment Management first reported a position in Jounce Therapeutics, Inc. Common Stock in Q1 2018 and held it in 3 quarters.
  • MetLife Investment Management's Jounce Therapeutics, Inc. Common Stock position peaked at $159K in Q1 2018.
  • 113 funds tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q1 2022.

Based on MetLife Investment Management's 13F filing for Q1 2022, filed 12 May 2022.